<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="166399">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01790698</url>
  </required_header>
  <id_info>
    <org_study_id>INFECT-FP7305340</org_study_id>
    <nct_id>NCT01790698</nct_id>
  </id_info>
  <brief_title>Systems Medicine to Study NSTIs</brief_title>
  <acronym>INFECT</acronym>
  <official_title>Improving Outcome of Necrotizing Fasciitis: Elucidation of Complex Host and Pathogen Signatures That Dictate Severity of Tissue Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Blekinge County Council Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Bergen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helmholtz Centre for Infection Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wageningen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Lyon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>LifeGlimmer GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anagnostics Bioanalysis GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lee Spark NF Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tel Aviv University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <authority>Sweden: Regional Ethical Review Board</authority>
    <authority>Denmark: Danish Health and Medicines Authority</authority>
    <authority>Denmark: The Danish National Committee on Biomedical Research Ethics</authority>
    <authority>Denmark: Danish Dataprotection Agency</authority>
    <authority>Norway: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This proposal focuses on highly lethal destructive tissue infections, i.e. necrotizing
      fasciitis and other necrotizing soft tissue infections (NSTIs), which are associated with
      high morbidity and mortality. The fulminant course of NSTIs demands immediate diagnosis and
      adequate interventions in order to salvage lives and limbs. However, diagnosis and
      management are difficult due to heterogeneity in clinical presentation, in co-morbidities
      and in microbiological aetiology. Thus, there is an urgent need for novel diagnostics and
      therapeutics in order to improve outcome of NSTIs. A comprehensive knowledge of diagnostic
      features, causative microbial agent, treatment strategies, and pathogenic mechanisms (host
      and bacterial disease traits and their underlying interaction network) is required for an
      improved diagnosis and management of NSTIs. The current proposal is designed to obtain such
      insights through an integrated systems biology approach in patients and experimental models.
      The project is based on a prospective NSTI patients cohort including a clinical registry to
      document clinical data and treatment strategies, combined with an isolate and biobank
      collection. The samples will be analyzed through advanced bioinformatics and computational
      modelling work flow to identify and quantify pathogen signatures and underlying networks
      that contribute to disease outcome. One aim is to translate clinical and systems biology
      data into development of novel diagnostics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be prospectively recruited at 5 clinical centers (Rigshospitalet, Karolinska
      University Hospital, Blekinge University, Sahlgrenska University and University of Bergen).
      Clinical definition criteria for NSTI: NSTI is a clinical diagnosis. Initial signs are the
      occurrence of erythema, pain or tenderness beyond margins of erythema and swelling. Imaging
      and laboratory tests have little predictive value in the early stage. The gold standard
      modality for diagnosis of NSTI remains operative exploration. Operative findings that are
      consistent with NSTI include &quot;dishwater or foul smelling discharge, necrosis or lack of
      bleeding and loss of the normal resistance of the fascia to finger dissection. A patient
      admitted for critical care and / or surgery due to severe soft tissue infection of the
      fascia, muscle or subcutaneous tissues will be enrolled in this NSTI study. The patients
      will be stratified based on several clinical parameters including among others SAPS score,
      presence of multiorgan failure, and hypotensive shock. This stratification serves to
      classify the patients in defined severity classes to be used in analyses and modeling.
      Detailed demographic and clinical information will be documented in the interactive database
      including: age, gender, medical history, clinical presentation (shock, multiorgan failure
      etc), treatment and outcome. Disease progress: The clinical database is to contain
      information on the spread of the infection at the different times of inspection/surgical
      intervention. Severity of the infections will be documented by use of the updated CREST
      classification scheme, SAPS III score, and the LRINEC score. Detailed information regarding
      antimicrobial therapy, surgical intervention, innovative therapy (IVIG and HBO) will be
      documented.

      Samples will be collected from all enrolled patients. Standard operating procedures will be
      generated and implemented at all sites to ensure a quality assured collection and handling
      of samples. Samples to be collected include (a) isolates, (b) blood samples to be processed
      for DNA, RNA and plasma/cells and (c) tissue biopsies in all patients whenever surgical
      interventions are indicated.  The samples will be analyzed using genomics, transcriptomics,
      metabolomics and proteomics.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <target_duration>3 Months</target_duration>
  <primary_outcome>
    <measure>Prognostic/diagnostic value (ROC curves: specificity, sensitivity, predictive values) of classification and severity scores in NSTIs</measure>
    <time_frame>3 months - further oservation up to 24 month may apply</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of IVIG and HBO-therapy on mortality rates in matched (defined by severity scores and aetiology) NSTI patients</measure>
    <time_frame>3 months - further observation up to 24 month may apply</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of hypotension, multiorgan failure, or fatal outcome of NSTI in relation to microbiologic aetiology</measure>
    <time_frame>3 months - further observation up to 60 month may apply</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Soft Tissue Infections</condition>
  <condition>Necrotizing Fasciitis</condition>
  <condition>Necrotizing Soft Tissue Infections</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Bacterial isolates, whole blood, plasma, tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Hospitalized patients with NSTI
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Necrotizing soft tissue infections

        Exclusion Criteria:

        Patients under the age of 18 years
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ole Hyldegaard, MD</last_name>
    <email>ole.hyldegaard@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ole Hyldegaard, MD</last_name>
      <email>ole.hyldegaard@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Anders Perner, MD</last_name>
      <email>anders.perner@regionh.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Erik Jansen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ole Hyldegaard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anders Perner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Tvede, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Bergen</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steinar Skrede, MD, PhD</last_name>
      <email>steinar.skrede@helse-bergen.no</email>
    </contact>
    <contact_backup>
      <last_name>Trond Bruun, MD</last_name>
      <email>trond.bruun@helse-bergen.no</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>SE-416 50</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Per Arnell, MD</last_name>
      <email>per.arnell@vgregionen.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Blekinge Hospital</name>
      <address>
        <city>Karlskrona</city>
        <zip>SE-371 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ylva Karlsson, MD</last_name>
      <email>ylva.karlsson@ltblekinge.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Folke Lind, MD, PhD</last_name>
      <email>folke.lind@karolinska.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://www.fp7infect.eu</url>
    <description>website of INFECT</description>
  </link>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 28, 2013</lastchanged_date>
  <firstreceived_date>February 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Anna Norrby-Teglund</investigator_full_name>
    <investigator_title>Professor, Coordinator of INFECT</investigator_title>
  </responsible_party>
  <keyword>Necrotizing fasciitis</keyword>
  <keyword>Streptococcus pyogenes</keyword>
  <keyword>Staphylococcus aureus</keyword>
  <keyword>Immunopathogenesis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fasciitis</mesh_term>
    <mesh_term>Soft Tissue Infections</mesh_term>
    <mesh_term>Fasciitis, Necrotizing</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
